CTOs on the Move

Cynvenio Biosystems Inc

www.cynvenio.com

 
Cynvenio is a cancer diagnostics company focused on transforming cancer treatment and management through the molecular analysis of cancer biomarkers in blood.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.cynvenio.com
  • 460 Ward Dr Ste e1
    Santa Barbara, CA USA 93111
  • Phone: 805.964.9700

Executives

Name Title Contact Details

Similar Companies

Ethical Review Committee

Ethical Review Committee is a Independence, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

American Institute of Gastric Banding

AIGB specializes in LAP-BAND surgery, an FDA-approved weight-loss surgery available to overweight and obese individuals. AIGB also provides a comprehensive, multi-disciplinary aftercare program to ensure the success of our LAP-BAND patients. Our

Health Alliance Plan

We are a non-profit, Michigan-based company and a subsidiary of the Henry Ford Health System, one of the nation`s leading health care systems. We provide health plans for everyone -- individuals and companies of all sizes. Since 1960, we`ve partnered with leading doctors, hospitals, employers and community organizations to enhance the lives of those we touch. We offer six distinct health insurance lines: • Group Insured Commercial • Individual • Medicare • Medicaid • Self-Funded • Network Leasing HAP also provides: • Award-winning wellness programs • Community outreach • Digital health tools • Disease management services • Personalized customer service

Nussentials

Nussentials is a Eufaula, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kolltan

Kolltan Pharmaceuticals is a private company founded in 2007 that is developing novel monoclonal antibody (mAb) drugs targeting receptor tyrosine kinases (RTKs). Kolltan's primary targets derive from seminal discoveries made in the laboratory of Dr. Joseph Schlessinger, Chairman of the Department of Pharmacology at the Yale School of Medicine, and in Kolltan’s laboratories. Dr. Schlessinger's laboratory has characterized a novel molecular mechanism underlying activation of RTKs providing, for the first time, a clear molecular explanation — at atomic resolution — for the oncogenic activity of mutations that have been identified in a variety of human cancers.